Organigram (OGI) Stock Price, News & Analysis

Company Overview

Organigram Inc. is a Canadian licensed producer of cannabis products. Organigram focuses on producing exceptional, indoor-grown cannabis for patients and adult recreational consumers, as well as developing global business partnerships.

Key Stats

• Today's Range: C$2.30 to C$2.42
• 50-Day Range: C$1.76 to C$2.38
• 52-Week Range: C$1.22 to C$2.72
• Volume: 115,252 shs
• Average Volume: 174,174 shs
• Market Capitalization: C$316.29 million
• P/E Ratio: 196.67
• Dividend Yield: N/A
• Price Target: C$3.33
• Consensus Rating: Buy

Organigram Stock Analysis - MarketRank™

Organigram scored higher than 58% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Organigram has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Organigram has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Organigram is 196.67, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 270.81.

Price to Earnings Ratio vs. Sector

The P/E ratio of Organigram is 196.67, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 83.19.

Price to Earnings Growth Ratio

Organigram has a PEG Ratio of 0.42. PEG Ratios below 1 indicate that a company could be undervalued.

Price to Book Value per Share Ratio

Organigram has a P/B Ratio of 0.83. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for OGI.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Organigram does not currently pay a dividend.

Dividend Growth

Organigram does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for OGI.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

4 people have searched for OGI on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Organigram insiders have not sold or bought any company stock.

Percentage Held by Insiders

31.32% of the stock of Organigram is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 4.08% of the stock of Organigram is held by institutions.

OGI Stock Analysis - Frequently Asked Questions

How have OGI shares performed this year?

Organigram's stock was trading at C$2.30 at the beginning of the year. Since then, OGI shares have increased by 2.6% and is now trading at C$2.36.

How do I buy shares of Organigram?

Shares of OGI stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

What other stocks do shareholders of Organigram own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Organigram investors own include Canopy Growth (CGC), Aurora Cannabis (ACB), Innovative Industrial Properties (IIPR), Aurora Cannabis (ACB), Canopy Growth (WEED), Aphria (APHA) and NVIDIA (NVDA).

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: Cannabis
• Current Symbol: TSE:OGI
• CIK: N/A
• Web: www.organigram.ca
• Phone: 844-644-4726
• Fax: N/A
• Employees: 987
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Organigram: C$3.33
• High Price Target: C$3.50
• Low Price Target: C$3.15
• Potential Upside/Downside: +40.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): C$0.01
• Trailing P/E Ratio: 196.67
• Forward P/E Ratio: 14.46
• P/E Growth: 0.42
• Net Income: -C$57.23 million
• Net Margins: -31.69%
• Pretax Margin: N/A
• Return on Equity: -17.59%
• Return on Assets: -5.56%

Debt

• Debt-to-Equity Ratio: 3.07
• Current Ratio: 3.36
• Quick Ratio: 2.62

Sales & Book Value

• Annual Sales: C$223.82 million
• Price / Sales: 1.41
• Cash Flow: C$0.61 per share
• Price / Cash Flow: 3.85
• Book Value: C$2.85 per share
• Price / Book: 0.83

Miscellaneous

• Outstanding Shares: 134,022,000
• Free Float: N/A
• Market Cap: C$316.29 million
• Optionable: Not Optionable
• Beta: 1.86